No takes yet. Share an insight, caveat, or question.
Review demonstrates advances in engineered interleukin-2 therapeutics for metastatic cancer, indicating potential to reduce systemic toxicity and broaden antitumor efficacy.
Tang et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: